Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells

Elodie Villa(Inserm), Emma Proïcs(Inserm), Camila Rubio‐Patiño(Inserm), Sandrine Obba(Inserm), Barbara Zunino(Inserm), Jozef P. Bossowski(Inserm), Romain Rozier(Inserm), Johanna Chiche(Inserm), Laura Mondragón(Inserm), Joel S. Riley(Cancer Research UK Scotland Institute), Sandrine Marchetti(Inserm), Els Verhoeyen(Inserm), Stephen W. G. Tait(Cancer Research UK Scotland Institute), Jean‐Ehrland Ricci(Inserm)
Cell Reports
September 1, 2017
Cited by 315Open Access
Full Text

Abstract

Mitophagy is an evolutionarily conserved process that selectively targets impaired mitochondria for degradation. Defects in mitophagy are often associated with diverse pathologies, including cancer. Because the main known regulators of mitophagy are frequently inactivated in cancer cells, the mechanisms that regulate mitophagy in cancer cells are not fully understood. Here, we identified an E3 ubiquitin ligase (ARIH1/HHARI) that triggers mitophagy in cancer cells in a PINK1-dependent manner. We found that ARIH1/HHARI polyubiquitinates damaged mitochondria, leading to their removal via autophagy. Importantly, ARIH1 is widely expressed in cancer cells, notably in breast and lung adenocarcinomas; ARIH1 expression protects against chemotherapy-induced death. These data challenge the view that the main regulators of mitophagy are tumor suppressors, arguing instead that ARIH1-mediated mitophagy promotes therapeutic resistance.


Related Papers

No related papers found

Powered by citation graph analysis